Managing the hyperinflammatory state with approved therapies in these patients could be of potential benefit in preventing lethal arrhythmias and pertinent mortality.
In the light of nonexistence of COVID-19 targeted antivirals or vaccines, supportive treatment remains the main goal of COVID-19 management. Furthermore, respiratory failure has been reported as the main cause of mortality; however, acute cardiac injury caused by fulminant myocarditis is also contributing to death in some patients. Cardiac troponin I has been found to be significantly increased in COVID-19 patients with severe form compared to those with milder form. 4 